Prosecution Insights
Last updated: November 20, 2026
Application No. 18/273,891

CELL STRAIN FOR PRODUCING BIOSIMILAR DRUG OF USTEKINUMAB AND PRODUCTION METHOD THEREFOR

Non-Final OA §103§112
Filed
Jul 24, 2023
Priority
Jan 25, 2021 — CN 202110099804.1 +1 more
Examiner
VIJAYARAGHAVAN, JAGAMYA NMN
Art Unit
1633
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Qyuns Therapeutics Co. Ltd.
OA Round
3 (Non-Final)
59%
Grant Probability
Moderate
3-4
OA Rounds
4m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
26 granted / 44 resolved
-0.9% vs TC avg
Strong +54% interview lift
Without
With
+54.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
46 currently pending
Career history
99
Total Applications
across all art units

Statute-Specific Performance

§101
5.7%
-34.3% vs TC avg
§103
31.7%
-8.3% vs TC avg
§102
14.7%
-25.3% vs TC avg
§112
33.1%
-6.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 44 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Acknowledgment is made of applicants' claim for foreign priority to Chinese applications CN 202110099804.1 filed on 01/25/2021. It is noted, however, that applicant has not filed a certified copy of the CN202110099804.1 application as required by 37 CFR 1.55. Applicants noted that a Permission to Access Application via Priority Document Exchange has been granted and provided the DAS code. Accordingly, the priority document has been retrieved from Patentscope (See PTO-892). The requirement under 35 U.S.C 119(e) has been satisfied. Status of Claims Claims 1 and 6 are pending and under exam. Claims 2-5 and 7-8 are cancelled Claim Interpretation The terms “substantially free of sialylated components” in claim 2 is not given explicit definition in the specification. However [0052] of the specification indicated that “sialylated components of Ustekinumab is between 11.87% and 25.56%, while QX001S expressed by the CHO-S cell line is substantially free of sialylated components.” As such the claim is interpreted to mean that the sialylated components are lower than 11.87%. WITHDRAWN REJECTIONS Claim Rejections - 35 USC § 112 Claims 3-4 and 6 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as failing to set forth the subject matter which the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the applicant regards as the invention. The rejection is withdrawn as it applies to the pending claims because of cancellation of the term “biosimilar drug”. MAINTAINED REJECTION Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1 and 6 remain rejected under 35 U.S.C. 103 as being unpatentable over Pippig et al (WO2018024770A1; Published Feb 8, 2018; hereinafter "Pippig;" See IDS of 08/01/2023), in view of You et al (Appl Microbiol Biotechnol. 2018 Jul; hereinafter "You;" See PTO-892). Regarding claims 1 and 6: Pippig taught a method of producing recombinant Ustekinumab antibody drug product, which is a fully humanized monoclonal antibody against a p40 subunit shared by human IL-12 and human IL-23; a heavy chain amino acid sequence of the fully humanized monoclonal antibody comprising instant SEQ ID NO:1, and a light chain amino acid sequence of the fully humanized monoclonal antibody comprising instant SEQ ID NO:3. (See Pippig claim 4). It is also noted that Pippig disclosed that the drug product has heavy chain sequence according to SEQ ID NO: 1 which is 100% identical to instant SEQ ID NO: 1 (See alignment below). Additionally, Pippig disclosed that the light chain has a sequence according to SEQ ID NO: 2, which is 100% identical to instant SEQ ID NO: 3 (See alignment below). It is noted that Pippig did not teach “an expression plasmid that expresses the fully humanized monoclonal antibody against the p40 subunit shared by human IL-12 and human IL-23; the expression plasmid comprises a nucleotide sequence encoding the heavy chain amino acid sequence of the fully humanized monoclonal antibody shown as SEQ ID NO:2, and a nucleotide sequence encoding the light chain amino acid sequence of the fully humanized monoclonal antibody shown as SEQ ID NO:4” as required by the claim. However, Pippig taught “culturing Chinese Hamster Ovary (CHO) host cells, genetically modified to express the heavy chain and the light chain of Ustekinumab, in a suitable culture medium under conditions that allow the cells to express the heavy chain and the light chain and to form the recombinant Ustekinumab antibody” (See Pippig Claim 1a). CHO, genetically modified to express the claimed drug product is interpreted to read on expression plasmid that expresses the fully humanized monoclonal antibody against the p40 subunit shared by human IL-12 and human IL-23. It is noted that the nucleic acid sequence claimed in the instant application: SEQ ID NO: 2 encoding a heavy chain and SEQ ID NO: 4 encoding the light chain was not taught or suggested by Pippig. However, You was directed to producing antibodies with high yield and quality is necessary for clinical applications of antibodies. (See You Abstract). You taught that the yield can be doubled by codon optimization and increased by 50% with the presence of untranslated regions (UTR) specifically for expression in CHO cells. You further taught that the combination of UTR with optimal codon and signal peptide to form an expression vector can result in yield improvement of 150% and correct N-terminal sequences. As such it was known that codon optimization and nucleotide sequence optimization strategies can improve recombinant antibody expression in CHO cells in view of You. It would have been obvious to a person of ordinary skill in the art to optimize the nucleotide sequences encoding the heavy and light chains of an antibody such as Ustekinumab for enhanced expression in CHO cells by modifying codons or other features with a reasonable expectation of success of improving expression without altering the encoded amino acid sequence. It is also noted that codon optimization represents a finite number of predictable solutions and selection of one optimized nucleotide sequence from among synonymous alternatives would have been routine. Query 1 EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRY 60 EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRY Sbjct 1 EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRY 60 Query 61 SPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSSS 120 SPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSSS Sbjct 61 SPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSSS 120 Query 121 STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG 180 STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG Sbjct 121 STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG 180 Query 181 LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGP 240 LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGP Sbjct 181 LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGP 240 Query 241 SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS 300 SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS Sbjct 241 SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS 300 Query 301 TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL 360 TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL Sbjct 301 TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL 360 Query 361 TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ 420 TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ Sbjct 361 TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ 420 Query 421 QGNVFSCSVMHEALHNHYTQKSLSLSPGK 449 QGNVFSCSVMHEALHNHYTQKSLSLSPGK Sbjct 421 QGNVFSCSVMHEALHNHYTQKSLSLSPGK 449 100% identity between SEQ ID NO: 1 of instant application to SEQ ID NO: 1 of WO2018024770A1 Query 1 DRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTIS 60 DRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTIS Sbjct 17 DRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTIS 76 Query 61 SLQPEDFATYYCQQYNIYPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL 120 SLQPEDFATYYCQQYNIYPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL Sbjct 77 SLQPEDFATYYCQQYNIYPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL 136 Query 121 NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV 180 NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV Sbjct 137 NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV 196 Query 181 THQGLSSPVTKSFNRGEC 198 THQGLSSPVTKSFNRGEC Sbjct 197 THQGLSSPVTKSFNRGEC 214 100% identity between SEQ ID NO: 3 of instant application to SEQ ID NO: 2 of WO2018024770A1 Response to Arguments and Claim Amendments Applicants argued that the claimed invention is not obvious because it relates to the successful development of a biosimilar antibody, which requires more than merely matching amino acid sequences and involves demonstrating similarity in quality, safety and efficacy. They emphasized that antibodies produced in different host cells, such as CHO-S cells versus those used in Pippig can exhibit significantly different glycosylation patterns, making biosimilar development unpredictable and challenging. The Applicant contends that the prior art does not provide motivation to use a CHO-S cell line or a reasonable expectation of success in achieving a biosimilar product. They further argued that their specific CHO-S cells clone was identified only after extensive screening of hundreds of candidates, indicating non-routine experimentation. Additionally, the Applicants asserted that the invention’s technical problem is not merely improving expression via codon optimization, but achieving a cell-line capable of producing a clinically validated biosimilar. Finally, they highlight that their product has successfully progressed through clinical trials and regulatory approval, supporting non-obviousness of the claimed invention. Applicants’ arguments and claim amendments have been carefully considered, but are not persuasive. Applicants argued that the claimed nucleotide sequence is not disclosed by Pippig in view of You and therefore unobvious. Additionally, the Applicants indicated that invention is not directed to improving expression efficiency. However, codon-optimization techniques are routinely used in biotechnology and especially in CHO cells as set forth above and such modifications do not alter the encoded amino acid sequence. As such selection of a particular nucleotide sequence encoding a known antibody is considered routine optimization involving finite number of predictable solutions, absent evidence of criticality or unexpected results. Applicant has not demonstrated unexpected results or properties relative to other codon-optimized sequences encoding the same antibody. Accordingly, these arguments are not persuasive. Applicants argued that they screened 694 candidates and only one specific clone exhibited the desired properties. It is acknowledged that screening and selection of high-producing or otherwise suitable clones is a standard step in development of recombinant cell lines for antibody production. The mere fact that a large number of candidates were screened or that only a subset exhibited desirable properties does not by itself render a claim unobvious, unless it is shown that selected clones exhibit unexpected properties, that are attributable to the claimed features and are commensurate in scope with the claims. Applicants have not provided comparative data demonstrating that the claimed clone exhibits unexpected or superior properties relative to other CHO-derived clones expressing the same antibody. Applicants argued at length about development of biosimilars highlighting their complexity and requirements of quality, safety and efficacy and asserted that their claimed cell-line produces a biosimilar product that has progressed through clinical trials and regulatory approval. While it is acknowledged that biosimilar development may require significant development and regulatory and experimental effort, such considerations are not dispositive of non-obviousness of the claimed subject matter. The relevant question is whether the claimed cell-line and expression constructs would have been obvious to a person of ordinary skill in the art at the time of invention, not whether subsequent regulatory approval was obtained. Additionally, neither Pippig nor You is relied upon for teachings regarding regulatory approval or biosimilar pathways. Accordingly, arguments directed to regulatory approval and biosimilar development are not commensurate with the scope of the rejection and are not persuasive. Should the Applicants contend that the claimed nucleotide sequences are non-obvious it would be helpful to provide evidence of criticality or unexpected results, such as for example, comparative data that these specific sequences provide advantages not achievable by routine optimization. It is noted that unexpected results should be commensurate in scope with the claims and should establish a nexus between the claimed features and alleged advantages. Conclusion No claim is allowed. No claim is free art. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAGAMYA VIJAYARAGHAVAN whose telephone number is (703)756-5934. The examiner can normally be reached 9:00a-5:00p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Christopher M. Babic can be reached at 571-272-8507. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JAGAMYA NMN VIJAYARAGHAVAN/ Examiner, Art Unit 1633 /EVELYN Y PYLA/Primary Examiner, Art Unit 1633
Read full office action

Prosecution Timeline

Jul 24, 2023
Application Filed
Jan 12, 2026
Non-Final Rejection mailed — §103, §112
Apr 13, 2026
Response Filed
May 12, 2026
Final Rejection mailed — §103, §112
Sep 14, 2026
Request for Continued Examination
Sep 15, 2026
Response after Non-Final Action
Nov 17, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12760288
METHOD FOR TARGETED MODIFICATION OF SEQUENCE OF PLANT GENOME
4y 5m to grant Granted Oct 13, 2026
Patent 12709733
CELL CULTURE MEDIA
4y 3m to grant Granted Aug 18, 2026
Patent 12681006
METHODS OF GENERATING HUMAN ENDOMETRIAL STROMAL FIBROBLASTS AND THREE-DIMENSIONAL MULTI-LAYERED HUMAN ENDOMETRIAL TISSUE COMPOSITIONS
4y 2m to grant Granted Jul 14, 2026
Patent 12667621
RNA FORMULATIONS SUITABLE FOR THERAPY
4y 6m to grant Granted Jun 30, 2026
Patent 12637700
NOVEL METABOLIC PATHWAY FOR PRODUCING ITACONIC ACID AND METHOD FOR PRODUCING ITACONIC ACID USING SAME
2y 5m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
59%
Grant Probability
99%
With Interview (+54.5%)
3y 8m (~4m remaining)
Median Time to Grant
High
PTA Risk
Based on 44 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month